Welcome to our dedicated page for Aridis Pharmaceuticals news (Ticker: ARDS), a resource for investors and traders seeking the latest updates and insights on Aridis Pharmaceuticals stock.
Aridis Pharmaceuticals Inc (ARDS) provides critical updates on infectious disease treatment development through its innovative drug formulation and delivery technologies. This news hub offers investors and healthcare professionals centralized access to verified company announcements and progress reports.
Find timely updates on clinical trial milestones, regulatory developments, and strategic partnerships. Our curated collection features press releases about novel drug candidates, manufacturing advancements, and research collaborations that demonstrate ARDS' leadership in ready-to-use therapeutic solutions.
Key updates include progress reports on proprietary anti-infective therapies, FDA communications regarding product candidates, and analyses of emerging treatment formats. All content undergoes strict verification to ensure accuracy and relevance for stakeholders.
Bookmark this page for direct access to ARDS' official announcements and expert analyses of their advanced formulation technologies. Regularly updated to reflect the company's latest developments in combating global health challenges through pharmaceutical innovation.
Aridis Pharmaceuticals (Nasdaq: ARDS) reported Q3 2021 results, noting significant advancements in its clinical pipeline. The company in-licensed suvratoxumab (AR-320) from AstraZeneca, with a Phase 3 study set to launch in early 2022. Positive Phase 2 data indicated a 32% relative risk reduction in pneumonia. Financially, cash was approximately $18.2 million, with revenues of $0.4 million driven by a milestone payment for AR-501. However, R&D expenses surged to $19.8 million, primarily due to the AR-320 license agreement, resulting in a net loss of approximately $21.0 million.
Aridis Pharmaceuticals (Nasdaq: ARDS) reported Q2 2021 results, highlighting a licensing agreement with AstraZeneca for suvratoxumab, a monoclonal antibody candidate for pneumonia prevention. The Phase 3 study is set to launch in Q4 2021, supported by €25 million from the EU. Phase 2 results showed a 32% pneumonia risk reduction overall and 47% in patients under 65. The company raised $25 million through a stock sale for clinical development and operations. Despite an increase in R&D and administrative expenses, the net loss rose to $5.5 million, surpassing Q2 2020's loss of $4.2 million.
Aridis Pharmaceuticals (Nasdaq: ARDS) announced a definitive agreement with a healthcare-focused institutional investor to sell 4,947,556 shares and warrants to purchase up to 2,473,778 additional shares at an effective price of $5.053 per share. This registered direct offering, set to close on August 4, 2021, is expected to generate approximately $25 million in gross proceeds. The proceeds will fund clinical development, working capital, and general corporate purposes. H.C. Wainwright & Co. is the exclusive placement agent for this offering.
Aridis Pharmaceuticals (Nasdaq: ARDS) has secured an exclusive worldwide license from AstraZeneca (LSE/STO/Nasdaq: AZN) for suvratoxumab, a monoclonal antibody candidate aimed at preventing pneumonia. This Phase 3-ready candidate follows positive Phase 2 results, showing a 47% reduction in pneumonia among S. aureus-colonized mechanically ventilated patients. Aridis will receive up to €25 million (~$30 million) in funding from the EU for the Phase 3 trial, while AstraZeneca will obtain an $11 million upfront payment and potential milestones worth $115 million.
Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS) announced that its COVID-19 monoclonal antibody (mAb) cocktail AR-712 effectively neutralizes the Delta variant of SARS-CoV-2 at a concentration of ~20ng/mL. Binding analyses indicate AR-712's efficacy against all variants of concern by CDC. The inhaled treatment, showing strong results in preclinical studies with a 1mg/kg dose, aims to lower treatment barriers for non-hospitalized patients. The company is progressing toward commencing clinical studies in late 2021, reinforcing its commitment to combat COVID-19.
Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS) reported Q1 2021 results, highlighting the addition of a second inhaled monoclonal antibody for COVID-19 treatment. The company anticipates launching a Phase 1/2 study for AR-712 in late 2021 and received developmental support from NIAID. Financially, Aridis ended Q1 with $10.5 million in cash, witnessing a net loss of $7.9 million, a slight increase from $6.5 million in the previous year. R&D expenses grew to $5 million, largely due to COVID-19 program investments. A $7 million financing was closed in March, bolstering their operational capabilities.
Aridis Pharmaceuticals (Nasdaq: ARDS) reported its Q4 2020 results, highlighting several milestones. The company announced positive preclinical data for AR-711, a monoclonal antibody treatment for mild-to-moderate COVID-19 patients, with clinical trials set for 2H 2021. The FDA has streamlined AR-501's Phase 2 trial for cystic fibrosis. Financially, the company reported a net loss of $5.8 million in Q4, an improvement from the previous year. Aridis successfully raised approximately $8.5 million in funding to support ongoing clinical trials.
Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS) announced that CEO Vu Truong will be interviewed on The RedChip Money Report on Bloomberg Network on March 27, 2021, at 7 p.m. local time. The discussion will focus on the company's progress in developing novel anti-infective therapies for serious infections. Aridis utilizes advanced technology platforms to create potent monoclonal antibodies for various infections, including ventilator-associated pneumonia. The interview will provide insights into upcoming milestones and the company's commitment to innovative therapies in the biopharmaceutical space.
Aridis Pharmaceuticals (Nasdaq: ARDS) announced a new out-licensing and product discovery agreement with Kermode Biotechnologies focused on zoonotic viruses. Kermode will finance product candidate discovery for African Swine Fever Virus (ASFV) utilizing Aridis' APEX platform. Under this collaboration, Kermode retains exclusive rights for veterinary mAbs and vaccines, while Aridis keeps exclusive rights for human-use products. The partnership aims to enhance the discovery of therapeutic solutions to mitigate the impact of ASFV and other viruses that could pose a pandemic risk.
